Saturday 17 October 2026 Export RGNX’s income statement to Excel — free account

REGENXBIO Inc.

REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024. In the quarter to June 2026, revenue grew 405.7%, EPS grew 131.2% and free cash flow fell 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.93 0.23 −3.21%

Follow RGNX

Alert me

Market cap: $472.7M
P/E: 0.0×
Fwd P/E: −2.2×
Dividend yield: —
F-score: 5/9
Altman Z: −2.57
Beneish M: −2.77
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.95

Total sells 0.94

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	—	—
Sell	—	—	—	—	1	—	1	1	1	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 472.65

Revenue 174.48

Net Income (196.43)

Free Cash Flow (249.67)

Net Debt (105.74)

Current Ratio 2.86

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.20)

P/S ratio 2.10

P/B ratio 5.10

Past 5Y EPS Growth —

This Y EPS Growth 10.54%

Next Y EPS Growth 13.81%

Next Y revenue growth (3.96%)

Next 5Y EPS Growth 26.41%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 3.46%

10-year low 10-year high

P/B against its own 10 years 89.50%

10-year low 10-year high

EV/Sales against its own 10 years 12.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	275	235	230	106
Receivables	25	20	26	107
Inventory	—	—	—	—
Other	20	14	13	12
	335	278	281	236

	2023	2024	2025	Q'26
Payables	23	23	21	16
ST’ Debt	—	—	—	—
Other	51	34	40	27
	130	103	118	83

Compound Annual Growth %

	10y	5y	3y
Sales	36.50%	1.97%	14.78%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(7.20%)	(22.93%)	(41.62%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	108	—	—	—
’25	89	21	30	30	170
’24	16	22	24	21	83
’23	19	20	29	22	90
’22	22	33	27	31	113
’21	19	22	31	399	470
’20	18	17	99	21	155

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(76)	(62)	—	—	—
’25	34	(49)	(56)	(52)	(124)
’24	(55)	(45)	(41)	(32)	(173)
’23	(81)	(47)	(49)	(41)	(218)
’22	(56)	(62)	(50)	(39)	(207)
’21	(44)	(36)	(43)	341	219
’20	(36)	(21)	(36)	39	(54)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(77)	(63)	—	—	—
’25	33	(50)	(56)	(53)	(126)
’24	(56)	(46)	(41)	(33)	(176)
’23	(86)	(50)	(51)	(42)	(228)
’22	(67)	(71)	(56)	(45)	(238)
’21	(75)	(56)	(61)	327	135
’20	(40)	(25)	(43)	27	(81)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.72)	0.43	—	—	—
’25	0.12	(1.38)	(1.20)	(1.30)	(3.76)
’24	(1.38)	(1.05)	(1.17)	(1.01)	(4.59)
’23	(1.53)	(1.66)	(1.41)	(1.43)	(6.02)
’22	(1.79)	(1.58)	(1.75)	(1.38)	(6.50)
’21	(1.20)	(1.36)	(1.37)	6.67	2.91
’20	(1.08)	(0.91)	0.23	(1.24)	(2.98)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.07	16.30	23.25	30.38	20.03	27.02	18.69	12.82	7.14	5.04	Analyst estimates 2026–2028 Powerpack
	High	24.55	36.10	85.10	63.21	54.97	50.26	35.73	25.54	28.80	15.41
People
People	Employees	107	139	192	257	306	372	401	344	353	371
	Revenue/emp, $m	0.04	0.07	1.14	0.14	0.51	1.26	0.28	0.26	0.24	0.46
Income, $m
Income, $m	Revenue	5	10	219	35	155	470	113	90	83	170
	Gross margin, %	79.10	83.56	95.59	76.61	76.89	88.98	51.61	58.76	59.72	88.09
	EBT	(63)	(73)	104	(97)	(106)	141	(280)	(264)	(227)	(194)
	EBT margin, %	(1,381.61)	(704.02)	47.65	(276.70)	(68.59)	30.03	(248.75)	(292.15)	(272.54)	(113.75)
	Net income	(63)	(73)	100	(95)	(111)	128	(280)	(263)	(227)	(194)
	Depreciation	3	5	5	6	9	15	18	18	16	16
Per share, $
Per share, $	Revenue	0.17	0.35	6.54	0.96	4.15	11.08	2.61	2.06	1.68	3.30
	Earnings	(2.38)	(2.45)	2.99	(2.58)	(2.98)	3.01	(6.50)	(6.02)	(4.59)	(3.76)
	Cash flow	(1.84)	(1.94)	3.13	(2.94)	(1.45)	5.16	(4.81)	(4.99)	(3.50)	(2.40)
	Capex	(0.31)	(0.24)	(0.40)	(0.32)	(0.72)	(1.98)	(0.71)	(0.23)	(0.05)	(0.05)
	Free cash flow	(2.15)	(2.18)	2.73	(3.25)	(2.17)	3.17	(5.52)	(5.22)	(3.55)	(2.45)
	Book value	6.12	6.13	15.22	12.27	10.13	18.01	11.96	7.13	5.24	1.99
	Shares, m	26	30	33	37	37	42	43	44	50	52
Valuation, ×
Valuation, ×	P/E	0.00	0.00	13.15	0.00	0.00	11.12	0.00	0.00	0.00	0.00
	P/S	106.46	99.90	6.42	42.66	10.94	2.95	8.52	8.89	4.59	4.36
	P/B	3.02	5.67	2.76	3.34	4.48	1.82	1.86	2.57	1.47	7.23
	EV/Sales	86.95	84.43	4.98	34.42	7.90	1.99	5.33	5.90	1.85	3.04
	EV/FCF	(7.04)	(13.47)	11.91	(10.16)	(15.09)	6.95	(2.52)	(2.33)	(0.88)	(4.10)
Cash, $m
Cash, $m	Operating cash flow	(49)	(58)	105	(108)	(54)	219	(207)	(218)	(173)	(124)
	Capex	(8)	(7)	(13)	(12)	(27)	(84)	(31)	(10)	(2)	(2)
	Free cash flow	(57)	(65)	91	(119)	(81)	135	(238)	(228)	(176)	(126)
Balance, $m
Balance, $m	Working capital	84	154	316	311	450	388	286	205	175	163
	Total debt	—	—	6	9	70	85	89	—	—	—
	Net debt	(90)	(161)	(314)	(296)	(476)	(457)	(365)	(275)	(235)	(230)
	Shareholders’ equity	162	183	509	450	378	764	516	312	260	103
Returns, %
Returns, %	ROA	(31.95)	(39.40)	26.92	(18.19)	(18.45)	14.03	(28.79)	(37.45)	(43.68)	(42.19)
	ROIC	(56.57)	(213.15)	28.25	(60.48)	0.00	32.58	(108.41)	(459.32)	(584.21)	0.00
	ROE	(33.27)	(42.45)	28.89	(19.76)	(26.87)	22.39	(43.78)	(63.65)	(79.49)	(107.00)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MNPR Monopar Therapeutics Inc.	$481.9M	— (loss-making)	—	—	n/m	−201.41% (below 0%: shrinking)	—	0.00%	Compare
ENTX Entera Bio Ltd.	$481.5M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%	Compare
NGNE Neurogene Inc.	$479.3M	— (loss-making)	— (loss-making)	—	n/m	−22.97% (below 0%: shrinking)	100.00%	0.00%	Compare
YDES YD Bio Limited	$477.5M	—	—	—	—	—	—	—	Compare
RGNX REGENXBIO Inc.	$472.7M	— (loss-making)	— (loss-making)	+405.73% (above 0%: growing)	n/m	−26.67% (below 0%: shrinking)	99.04%	27.09%
ARVN Arvinas, Inc.	$468.2M	53.6×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%	Compare
CBIO Crescent Biopharma, Inc.	$463.6M	— (loss-making)	— (loss-making)	+1,038,900.00% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	100.00%	0.00%	Compare
ALLO Allogene Therapeutics, Inc.	$463.0M	— (loss-making)	— (loss-making)	+20,990.91% (above 0%: growing)	n/m	+17.73% (above 0%: growing)	100.00%	(1,011.21%)	Compare
ALT Altimmune, Inc.	$459.1M	— (loss-making)	— (loss-making)	+520.00% (above 0%: growing)	n/m	−25.27% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$472.8M	—	—	+1,014.73%	—	−22.97%	100.00%	0.00%

All 614 Biotechnology stocks →

REGENXBIO Inc. (RGNX) key facts

Concern: REGENXBIO Inc. reported a net loss of $193.9 million, or a loss of $3.76 per share, for fiscal 2025.
Strength: REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.
REGENXBIO Inc. (RGNX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RGNX traded at $6.93, a market capitalization of $472.7 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.1× sales.
Return on equity was −107.0% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −2.57 (distress zone) for fiscal 2025.